Off-resonance saturation as an MRI method to quantify ferritin-bound iron in the post-mortem brain

Lucia Bossoni¹, Ingrid Hegeman-Kleinn², Sjoerd G. van Duinen², Lena H. P. Vroegindeweij³, Janneke G. Langendonk³, Lydiane Hirschler¹, Andrew Webb¹, Louise van der Weerd¹

¹C. J. Gorter Center for High field MRI, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
²Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
³Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Porphyria Center Rotterdam, Erasmus University Medical Center, Rotterdam, The Netherlands.

Running Title: Off-resonance saturation to image ferritin iron

Corresponding author:
Lucia Bossoni, PhD
Leiden University Medical Center
PO Box 9600, 2300 RC Leiden, The Netherlands
T. +31 71 526 44 77 | E. l.bossoni@lumc.nl

Word Count: 4655
Abstract

Purpose
To employ an Off-Resonance Saturation (ORS) method to measure the ferritin-bound iron pool, which is an endogenous contrast agent which can give information on cellular iron status.

Methods
An ORS acquisition protocol was implemented on a 7T preclinical scanner and the contrast maps were fitted to an established analytical model. The method was validated by correlation and Bland-Altman analysis on a ferritin-containing phantom. Ferritin-iron maps were obtained from post-mortem tissue of patients with neurological diseases characterized by brain iron accumulation, i.e. Alzheimer’s disease, Huntington’s disease and aceruloplasminemia, and validated with histology. Transverse relaxation rate and magnetic susceptibility values were also obtained for comparison.

Results
In post-mortem tissue, the ferritin-iron contrast strongly co-localizes with histological iron staining, in all the cases. Quantitative iron values obtained via the ORS method are in agreement with literature.

Conclusions
Off-resonance saturation is an effective way to detect iron in grey matter structures, while mitigating for the presence of myelin. If a reference region with little iron is available in the tissue, the method can produce quantitative iron maps. This method is applicable in the study of brain diseases characterized by brain iron accumulation and complement existing iron-sensitive parametric methods.

Keywords  Iron, post-mortem MRI, ferritin, neurodegenerative diseases
Introduction

Physiological iron is distributed heterogeneously within the brain, with the structures richest in iron being localized within the basal ganglia. The distribution of iron throughout the brain is likely related to its fundamental biological processes, which involve oxygen transport, DNA synthesis, and mitochondrial respiration. In contrast, the dysregulation of iron homeostasis is associated with neurotoxicity via the formation of reactive oxygen species (ROS), lipid peroxidation, and ferroptosis, a form of cell death characterized by phospholipid oxidation. Iron is also thought to trigger inflammation which can, in turn, lead to additional cellular iron release.

Brain iron accumulation is a common phenomenon of several neurodegenerative diseases, despite their different pathological hallmarks. Examples are Alzheimer’s disease, Huntington’s disease, and the neurodegeneration with brain iron accumulation (NBIA) group of disorders of which aceruloplasminemia (ACP) is a rare phenotype.

One of the primary cytoplasmic proteins responsible for intra- and extracellular iron storage is ferritin. Ferritin is composed of a 24-subunit shell (apoferritin) which plays three important roles in iron regulation: it binds cytoplasmic Fe; it oxidizes Fe into Fe (as antioxidant protection); and it stores iron in the form of a biocompatible nano-mineral, ferrihydrite, or a mixture of ferrihydrite and other minerals. Since the core of ferritin can bind up to ~5000 iron atoms, the nanoparticle’s saturated magnetic moment can reach ~300 μB. Ferritin-bound iron levels constitute ~80% of total non-heme iron and therefore ferritin is commonly used as a reporter of tissue iron status. Although ferritin-bound iron is unlikely to contribute directly to oxidative stress, its levels are related to the labile iron pool, which is implicated in neurotoxicity.

MRI is very sensitive to the magnetic field perturbation caused by iron ions and iron nanoparticles which have superparamagnetic properties. In the presence of iron, diffusing water molecules probe a broad distribution of magnetic fields. Consequently, a time-dependent phase is accumulated, leading to reduced T2 and T* relaxation times. Ferritin-bound iron is the (physiological) iron form having the largest effect on the MRI signal due to its large susceptibility and abundance. The most sensitive MR methods for the detection of iron are the Field Dependent Transverse Relaxation Rate Increase (FDRI) and R* and R* mapping, and Quantitative Susceptibility Mapping (QSM). Although quantitative maps of transverse relaxation rates and tissue magnetic susceptibility have already shown benefits in the clinic, these parameter are also influenced by myelin content, fiber orientation, tissue microstructure, neuronal loss and iron aggregation. Additionally, QSM reconstructions can be affected by the non-local nature of the inverse problem that relates magnetic field perturbation to magnetic susceptibility, and this impairs quantitative analysis.
In this work, we show how an off-resonance saturation (ORS) method, earlier introduced for the detection of iron-oxide contrast agents, can be employed to assess ferritin-bound iron levels in the post-mortem brain and overcome some of the limitations of conventional mapping methods. We validated the method in a brain phantom, and we employed it to characterize the ferritin-bound iron levels in post-mortem material obtained from three patients affected by neurological diseases associated with increased brain iron. We assessed the ferritin-bound iron maps against QSM and $R_2^*$ maps, and histopathological staining for ferric iron, ferritin and myelin.

**Methods**

**Tissue selection and phantom preparation**

A ferritin-agar phantom was prepared by adding horse spleen ferritin (Sigma, ref. F4503) to a 1.5% agar solution. Phantoms with different iron concentrations were prepared: 0 mM, 1.3 mM, 4.0 mM, 7.0 mM, 10.3 mM and 15.1 mM. The iron concentration was estimated by multiplying the ferritin concentration by the average loading of the protein i.e. 2500 iron/ferritin.

Formalin-fixed tissue blocks extracted from three diseased brains were studied. Brain material from a patient with Huntington’s disease (HD), a patient with Alzheimer’s disease (AD) and a patient with aceruloplasminemia (ACP) was obtained from the Pathology department of the LUMC, the Netherlands Brain Bank, and the Erasmus Medical Center, respectively. Patient’s informed consent was obtained from each respective brain bank. For each case, a disease-relevant area was chosen: the striatum for the HD case; the striatum and the globus pallidus for the ACP case; and the middle temporal gyrus for the AD case. The tissue blocks were rehydrated in phosphate buffered solution (PBS) for 24 hours prior to the scan, to partially restore transverse relaxation times. Subsequently, the tissue was scanned in a hydrogen-free solution (Fomblin® LC08, Solvay).

**MRI data acquisition**

MRI data were acquired on a 7T preclinical scanner (Bruker Biospin, Ettlingen, Germany) using a 38 mm linear birdcage transmit-receive coil (T10327V3) with eight legs.

To compare the iron maps obtained with ORS to standard QSM and $R_2^*$ maps, $R_2^*$-weighted images were acquired using a 3D multiple gradient echo (MGE) sequence. The echo time (TE) was optimized for the tissue block under study since the transverse relaxation (and iron load) largely varies per region and disease. The acquisition parameters are summarized in Table 1.
ORS images were derived from 2D steady state free precession (SSFP) images (FISP-FID) with
TE/TR=3/6ms; inter-scan delay TR =2 s; FA= 10 degrees. A ‘control’ magnitude image (M_{control}),
without saturation pulses, was also acquired. Saturated images (M_{sat}) were produced by a saturation
module consisting of six hyperbolic secant pulses of bandwidth 500 Hz (B_{1}=1.36 µT), followed by a
spoiler gradient of 3 ms duration. The off-resonance saturation pulses were phase-cycled to improve
the spoiling. A list of M_{sat} was obtained upon varying the frequency of the off-resonance pulse.
Details of the off-resonance acquisition are reported in Table 2.
Raw data acquired in this study are freely available at the link:
http://dx.doi.org/10.17632/nkznjnjwpw.1

MRI Data Processing
MGE-magnitude images were fitted on a pixel-by-pixel basis to a mono-exponential decay function^{23},
after ruling out the presence of multi-components, using the Levenberg–Marquardt curve-fitting
algorithm to derive the transverse relaxation rate R_2. The noise floor was reached in the last 2 or so
echoes in some regions of the tissue (ACP) containing extremely high iron accumulation but did not
affect the overall fitting quality. To more accurately fit the data, we excluded the pixels with
intensities at the noise level.
Susceptibility values (χ) were obtained from the phase images with the STI-Suite software (version
2.2). Phase unwrapping of the measured phase images and removal of the background field were done
with iHARPERELLA^{42}, while magnetic susceptibility estimation and streaking artifact correction
were performed with the ‘iLSQR’ algorithm^{43}. Raw susceptibility values are reported, as no reference
region was available in these small tissue samples.

Figure 1 illustrates the pipeline of the ORS analysis. ORS images (M_{ors}) were obtained from the
subtraction: M_{ors} = M_{control} - M_{sat}. Contrast (C) maps were obtained by subtracting the mean intensity
of M_{ors} in a region of reference (ROR) from the M_{ors}^{40}. Under the assumption that the ROR contains
no iron, the contrast (C) can be written as the product of the fraction of protons (φ) saturated by the
ORS pulses and the intensity of the control image (C=M_{control} φ). In our work, only positive frequency
offsets were chosen, to exclude Nuclear Overhauser Effects (NOE)-related artifacts and to speed up
the acquisition. The saturated fraction of protons, as derived by Delangre et al.^{40}, is given by:
\[ \phi = \frac{1}{\pi} \arctg(\alpha(v_0 - \delta v + \Delta v/2)) - \arctg(\alpha(v_0 - \delta v - \Delta v/2)) \]
Where \( a = \frac{3\sqrt[3]{\gamma} \gamma M_{\text{sat}}}{2\pi \gamma \gamma \gamma} = \frac{\alpha}{[Fe] B_{eq}} \), \( \gamma \) is expressed in MHz/T, \( B_{eq} = \frac{\mu_0 M_S}{3} \) is the stray field (in Tesla) at the equator of a nanoparticle with saturation magnetization \( M_S \), \([Fe]\) is the iron concentration (in mM), and \( \nu_{\text{max}} \) is the molar volume of ferrihydrite\(^{45}\) and equal to 5.4x10\(^{-6}\) m\(^3\)/mol=5.4x10\(^{-6}\) mM\(^{-1}\), and 

\[ \alpha=3.6 \times 10^3 \text{ T (Hz mM)}^{-1} \] (See Supplementary material for further details). A frequency offset \( (\delta \nu) \) was added to account for resonance frequency shifts. Since \( N=6 \) saturation pulses were used to enhance the saturation\(^{46}\), the final expression for the contrast becomes:

\[ C(\nu_0) = N M_{\text{control}} \varphi(\nu_0)+\text{off} \]  

\[ \text{[2]} \]

\( M_{\text{control}} \) is weighted by the proton density, relaxation times, and flip angle\(^{47}\). The offset \( (\text{off}) \) term in the equation above was introduced to account for residual MT effects and imperfect saturation. Finally, the contrast map was fitted to equation [2] to derive the iron concentration, with the equatorial field as a fixed parameter. The agreement between the fitted iron concentration and the known iron concentration was assessed with correlative and Bland-Altman analyses.

**Histopathological validation**

The same tissue blocks used for MRI were employed for histology. Tissue blocks were embedded in paraffin and sliced with a microtome into 5 \( \mu \)m and 20 \( \mu \)m thick sections. The 20 \( \mu \)m sections were employed for non-heme iron detection (Meguro staining), according to Van Duijn et al.\(^{48}\). After deparaffinization, the tissue sections were incubated for 80 min in 1% potassium ferro-cyanide, washed, followed by 100 min incubation in methanol with 0.01M NaN\(_3\) and 0.3% H\(_2\)O\(_2\). Subsequently, sections were washed with 0.1M phosphate buffer followed by 80 min incubation in a solution containing 0.025% 3’3-diaminobenzidine- tetrahydrochloride (DAB, Sigma-Aldrich) and 0.005% H\(_2\)O\(_2\) in 0.1M phosphate buffer. The reaction was stopped by washing with tap water. The 5 \( \mu \)m slices were used for additional staining: non-heme (mostly trivalent) iron was detected with Perl’s Prussian blue (Merck 1.04984.0100); and immunohistochemical detection of myelin was done with anti-myelin PLP antibody (Bio-Rad, MCA 839G) with second antibody Rb-aMs/biotin (DAKO) for 1h at room temperature, followed by ABC (avidin-biotin-complex/HRP, ABC Elite Kit, Vector) for 30 min at room temperature. Immunohistochemical detection of ferritin was done with ferritin antibody (Bethyl A80-140, dilution 1:1000, overnight incubation at room temperature), with as second step antigoat/biotin (Bethyl A50-204B, dilution:1:1000, 1h incubation at room temperature), followed by ABC incubation for 30 min at room temperature. After the ABC treatment, the tissue was rinsed three times with phosphate buffered saline and incubated in 0.05% DAB (Sigma-Aldrich) with 15 \( \mu \)l 30%H\(_2\)O\(_2\)/100ml for 5-10 minutes. After rinsing several times with demineralized water, the slices were counterstained for 30 s with Harris haematoxilin and washed for 5-10 mins with tap water. Finally, the tissue sections were dehydrated with ethanol 70%, 96%, 100%, and xylene.
Correlation between histology and ORS imaging

To quantify the degree of agreement between the histological staining for iron with the ferritin-bound iron concentration derived from the ORS method, oval regions of interest (ROI, N=30) were drawn in the grey matter regions of the ferritin-bound iron maps and ORS maps. The iron staining image was manually co-registered (affine transformation) to the MRI maps with the TrackEM2 plugin in ImageJ. The registered image stack was converted to an 8-bit greyscale image. Oval ROIs were carefully drawn and propagated between the iron histological map and the MRI map with the ROI manager tool. Mean grey values from the predefined ROIs were quantified, after inspecting for the precise placement of the ROIs. Pearson’s correlation coefficient (\(\rho\)) of the association between histological staining intensity and the ferritin-bound iron map was calculated per case.

Results

Validation on ferritin phantom

Figure 2 shows the iron map obtained for the ferritin-loaded phantom and the ROI analysis on the sample’s compartments. The region of reference (ROR) was drawn in the middle of the phantom containing only agar (Figure 1). The best-fitting results were obtained when fixing \(B_{eq}=1\) mT, which is very close to the theoretical value for ferritin (see Supplementary Information). The fitted iron value agrees well with the nominal iron concentration, as assessed by the correlative plot in Figure 2C. Furthermore, the agreement between the iron concentration derived from the ORS map and the nominal iron concentrations was assessed by Bland-Altman analysis (Figure 2D)\(^{49,50}\), considering the latter parameter as the reference value. No data fell outside of the limits of agreement and no systematic bias was detected, at the 5% level of significance.

Application to post-mortem material

Figure 3 shows the results obtained for the middle temporal gyrus of the AD case. A comparison is shown between the MRI parametric maps, i.e. \(R_2^*\), QSM and the ORS-based ferritin-bound iron map (termed [Fe]\text{ORS} map in the rest of the manuscript) and histology, i.e. myelin, iron and ferritin. Elevated \(R_2^*\) levels are seen in the myelin-rich white matter and in the more superficial cortical layers. In the QSM map, negative susceptibility is predominantly detected in the white matter. The [Fe]\text{ORS} map shows a strong localization of the iron in the cortex and (partially) in the white matter, thus largely mirroring the QSM paramagnetic contrast and the histological staining of iron and ferritin (protein), while it appears poorly correlated to the myelin histological staining. Across all tissue blocks, the Perl’s staining was considerably weaker than then Meguro staining, as earlier reported\(^{48,51}\).
and correlated less with the ferritin map, therefore our quantitative analysis was based on the Meguro staining for iron, only.

The tissue block containing the striatum of the HD case (Figure 4) shows high $R_2^*$ primarily in the putamen (PU), some connecting fibers of the internal capsule (IC), and a thin stripe of the atrophied caudate nucleus (CN). The susceptibility map looks heterogeneous, but with an overall positive susceptibility in the PU and CN. The IC shows a characteristic striped appearance of alternating positive and negative susceptibility. The [Fe]ORS map shows a localized increase of iron in the PU, a thin stripe of the CN and of the external capsule. This map mirrors the iron staining, with the exception of the external capsule and some connecting fibers of the internal capsule, which show no contrast in the [Fe]ORS map, probably due to partial volume effects. The histological staining for ferritin, iron and the [Fe]ORS map are largely opposite to the myelin-positive regions, which display negative susceptibility in the QSM map. Note that the [Fe]ORS map shows iron contrast in a substantial part of the external capsule, possibly due to iron in myelin.

Finally, the tissue block obtained from the ACP patient (Figure 5) shows high $R_2^*$ in the putamen, some connecting fibers of the internal capsule, the caudate nucleus and the globus pallidus ($R_2^*\sim$0.3-0.6 ms$^{-1}$), similarly to the HD case. The QSM map is relatively smooth in the white matter regions, while the grey matter is heterogeneous and presents a ‘patchy’ appearance (also observed in the MGE images) which hinders quantitative analysis. The [Fe]ORS map on this tissue block shows diffuse iron across both white and grey matter structures, except for the superior part of the internal capsule, where the ROR was drawn. The histological iron staining (Meguro) appears very intense across the whole slice, with a slightly higher intensity in the caudate nucleus and the globus pallidus, which is also captured by the [Fe]ORS map. In contrast to the previous cases, the ferritin staining is rather weak across the whole slice, as discussed below. Additional histological results on all the tissue blocks are found in the Supplementary material (Figures S2-S5).

**Discussion:**

In this work we demonstrate how a method based on diffusion-mediated off-resonance saturation (ORS)\textsuperscript{79} can detect ferritin-bound iron concentrations from post-mortem brain material of an Alzheimer’s (AD), Huntington’s (HD) and aceruloplasminemia (ACP) patient. This method can be translated in vivo to evaluate tissue iron load and therapeutic efficacy on a pathophysiological level.

Water molecules diffusing around iron particles can be selectively excited by ORS pulses, based on the correspondence between frequency offset and distance from the nanoparticle: the larger the frequency offset, the closer the protons are to the dipolar-field source. It has been shown that the
positive contrast obtained by this method is distinct from, and can be observed also in the presence of, MT effects\textsuperscript{39}. Although the ORS-method was originally introduced to quantify/detect superparamagnetic iron-oxide nanoparticles (SPION), here we show that ORS can also be employed to assess the presence and the concentration of ferritin-bound iron, by virtue of the super-paramagnetic properties of the protein and its high concentration across the brain. Our results on the agarose phantom show good agreement between nominal and fitted iron concentrations and support the use of the method for iron quantification.

Visual comparison between the parametric MRI maps acquired in this study shows some advantages of the ORS method: i) iron load appears highly localized in specific brain regions (mainly the gray matter); ii) the white matter structures, which are highly myelinated, are predominantly masked out in the [Fe]ORS maps, except for the ACP tissue where iron appears largely diffuse throughout the whole slice; iii) the [Fe]ORS map largely mirrors the QSM map, when the latter is free from artefacts; iv) the strength of the association between the [Fe]ORS maps and the iron staining was moderately high in all cases ($\rho>0.5$), and independent on the disease type.

The appearance of the ferritin-bound iron map in the tissue block obtained from the AD patient suggests that, when looking at the temporal lobe, iron preferentially accumulates in the cortical grey matter. This is in agreement with previous $R_2$\textsuperscript{52,53} and QSM studies\textsuperscript{54} reporting increased cortical iron levels in patients with AD or mild cognitive impairment, which was associated with AD pathological hallmarks, and an increased risk of cognitive decline. Magnetometry studies carried out on both sporadic and genetic types of AD have also found that ferritin-bound iron is more abundant in the AD group than in age- and gender-matched healthy controls\textsuperscript{55,56}.

Previous analytical studies have detected significant increase in the total iron content of the temporal lobe of AD patients with respect to controls\textsuperscript{57,58}. However, the absolute iron concentrations ranged from $\sim$30 ng/mg\textsuperscript{58} to 120 ng/mg (wet weight)\textsuperscript{59}, since age, gender, disease state and technique sensitivity can impact the measured iron values. The highest cortical ferritin-bound iron concentrations detected in our tissue block were $1.37 \pm 0.25$ mM (mean $\pm$ sd), corresponding to 76.45 $\pm$ 13.95 ng/mg, which is in agreement with the estimate of ferritin-bound iron by magnetometry in the AD temporal cortex\textsuperscript{56}, after correcting for dry weight mass-loss.

The ferritin-bound iron map of the tissue block from the HD patient shows an increase of iron in the putamen and part of the atrophic caudate nucleus. Alterations in brain iron metabolism with increased iron accumulation have been previously identified by MRI in the striatal nuclei of patients with Huntington’s disease\textsuperscript{26,60}. Iron accumulation in these structures seems to occur early on during the disease process\textsuperscript{61}, suggesting a key role of iron in the initiation and progression of the disease\textsuperscript{11}. In fact, in vivo MRI studies at both 3T and 7T have shown that iron accumulation\textsuperscript{62} is associated with
tissue atrophy of basal ganglia structures and is already present in the premanifest phase of HD. Our mean fitted iron concentration in the putamen was $4.66 \pm 1.35$ mM, equivalent to $260.0 \pm 75.33$ ng/mg, which agrees well with iron concentrations measured by inductively coupled mass spectrometry.

Finally, the ferritin-bound iron map of the ACP tissue block shows a very diffuse iron load, with mean iron values of $2.57 \pm 1.45$ mM, in the putamen, which is about 50% lower than our recent magnetometry study which quantified ferritin-iron in the same structure of the same patient. This is likely due to the combination of very fast relaxation times and the lack of an appropriate ROR in the slice. In contrast to AD and HD, iron accumulation in ACP is directly related to its genetic background, and results from the absence of functioning ceruloplasmin. The lack of ceruloplasmin-mediated oxidation of ferrous iron ($\text{Fe}^{2+}$) to ferric iron ($\text{Fe}^{3+}$) impairs iron efflux from astrocytes, and leads to massive iron accumulation within these cells, while neurons that are mainly dependent on the supply of iron from astrocytes are probably iron-starved. Although ferritin-bound iron appears to be by far the most abundant iron form in the aceruloplasminemia brain, these observations are based on patients with end-stage aceruloplasminemia, and it remains unclear how the increase in either total iron levels, as suggested by previous $R_2^*$, and QSM studies, or in the amount of ferritin-bound iron, are associated with the clinical course of the disease. The apparent contradiction with the weak ferritin staining for the tissue block can perhaps be resolved by considering that the long formalin fixation (~ 5 years) can impact the tissue quality and staining efficiency.

Different MRI methods, in addition to those already mentioned, have been used to estimate the effect of ferritin nanoparticles on the MRI parameters. In fact, ferritin-bound iron has long been identified as the main source of iron-driving contrast, given the large abundance of the protein in the brain and its magnetic properties. The magnetic susceptibility of a single ferritin protein was estimated as $\chi = 520$ ppm for a fully loaded particle, although this value might be an upper limit.

Ferritin-iron displays a peculiar linear inverse dependence of $T_2$ with $B_0$ field, a trend that is retained in brain tissue and is attributed to the ‘fingerprint’ of iron stores. This characteristic is exploited by the Field Dependent Transverse Relaxation Rate Increase (FDRI) metrics. A method based on direct saturation to sensitize image contrast based on iron load has demonstrated a linear relation with the tissue iron content and an improved gray matter-white matter contrast with respect to $T_2$-weighted images. The ORS method here proposed differs in the acquisition protocol, with a much larger ORS frequency range being probed here, and in the data post-processing.

When inspecting the ferritin-bound iron maps, some caveats should be considered. Firstly, our method assumes that the only source of contrast are ferritin nanoparticles carrying ferrihydrite in the core. This is a simplification, as ferrihydrite is probably also included in hemosiderin. Also, magnetite/maghemite is located in the brain either outside or within ferritin. Recent studies,
though, have shown that these additional minerals are approximately three orders of magnitude less abundant than ferritin-bound iron.\textsuperscript{55,56}

Secondly, we assumed that the iron loading of each ferritin protein was approximately equal to half of the maximum filling capacity of the homonymous protein, while lower iron loading ranges, i.e. between 1500-1850 iron ions within each ferritin protein, have been reported for AD brain tissue and controls\textsuperscript{77}. However, since the magnetization of the ferritin particle would not, or only minimally, depend on the iron loading, this does not significantly affect the total ferritin-iron concentrations reported here.

Additionally, the ferritin-bound iron maps were obtained from contrast maps that were referenced to a region (ideally) without iron. Therefore, the iron concentrations here displayed cannot be considered as absolute. This is especially clear in the case of the ACP tissue block, where the ferritin-bound iron map shows comparable iron concentrations to the HD case, despite the striking difference in the Meguro staining. This is probably due to the lack of a good ROR in the ACP tissue block.

Finally, T\textsubscript{2} maps (not acquired in this study) can provide additional information on the degree of iron accumulation and, in combination with the T\textsubscript{2}* maps, could offer valuable information on the effective size of iron-rich compartments\textsuperscript{78}.

In conclusion, we adapted an ORS method\textsuperscript{46,39} to quantify the ferritin-bound iron pool in the post-mortem brain tissue of three patients affected by neurological diseases associated with increased brain iron. This method can aid the interpretation of R\textsubscript{2}* and QSM maps, especially when these are confounded by reconstruction artifacts or the co-presence of iron and myelin. The accuracy of the ferritin-bound iron map depends on the availability, within the tissue, of a region without (or with little) iron content with respect to the region of interest. We foresee that this method will find use in the study of the progression of neurodegenerative diseases characterized by brain iron accumulation and the assessment of iron chelation therapy.

Author contributions

Lucia Bossoni: Conceptualization, Methodology, Software, Investigation, Writing – Original Draft, Visualization, Project Administration; Ingrid Hegenann-Kleinn: histological analysis; Sjoerd van Duinen: supervision of the histological analysis; Lena H. P. Vroegindeweij: Resources, Writing – Review & Editing; Janneke G. Langendonk: Resources, Writing – Review & Editing; Lydiane Hirschler: Software, Writing – Review & Editing; Andrew G. Webb: Methodology, Resources, Writing – Review & Editing; Louise van der Weerd: Methodology, Resources, Writing – Review & Editing.

Acknowledgements
The authors are grateful to E. Suidgeest, E. Ercan and M. Bulk for assistance in the lab and useful discussions.

**Funding**

This study was supported by the Netherlands Organization for Scientific Research (NWO) through a VENI fellowship to L.B. (0.16.Veni.188.040).

**Declarations of interest:** none.

**Tables**

**Table 1.** Summary of the acquisition parameters for the MGE sequence, with eight echoes ($N_{echo}$). $TE_1$ refers to the first echo time, $\Delta TE$ refers to the inter-echo time. TR is the recovery time and FA the flip angle. Abbreviations: HD: Huntington’s disease, ACP: aceruloplasminemia, AD: Alzheimer’s disease.

| Sample | Pixel size (mm$^3$) | FA (degrees) | Averages | TR (ms) | $TE_1$ (ms) | $N_{echo}$ | $\Delta TE$ | Total scan time |
|--------|---------------------|--------------|----------|---------|-------------|------------|------------|----------------|
| HD     | (0.15)$^3$         | 25           | 20       | 107.3   | 5.2         | 8          | 4.34       | 3h26m          |
| ACP    | (0.15)$^3$         | 25           | 20       | 130.4   | 1.96        | 8          | 2.21       | 3h55m          |
| AD     | (0.15)$^3$         | 25           | 20       | 107.3   | 5.2         | 8          | 4.34       | 3h26m          |

**Table 2.** Summary of the acquisition parameters for the ORS-SSFP acquisition. Symbols: BW: ORS Pulse bandwidth; $\nu_0$: frequency of the off-resonance saturation pulse; $\Delta \nu_0$: interval between ORS frequencies, HD: Huntington’s disease, ACP: aceruloplasminemia, AD: Alzheimer’s disease.

| Sample | BW [Hz] | $\nu_0$ range [Hz] | $\Delta \nu_0$ [Hz] | Total scan time | Pixel size (mm$^3$) | Reference for contrast calculation (ROR) |
|--------|---------|---------------------|---------------------|-----------------|---------------------|----------------------------------------|
| Phantom| 500     | 250-649             | 7                   | 1.3h            | 0.3x0.3x2           | Agar-only compartment                   |
| HD     | 500     | 250-700             | 5                   | ~8h10min        | 0.15x0.15x2         | Internal capsule                        |
| ACP    | 500     | 250-700             | 5                   | ~8h10min        | 0.15x0.15x2         | Internal Capsule                        |
| AD     | 500     | 250-700             | 5                   | ~8h10min        | 0.15x0.15x2         | Cortical white matter                   |
**Figure Captions**

**Figure 1. Analysis pipeline.** After the acquisition of the non-saturated images ('control'), the saturated images are acquired, and the ORS image is derived. The Z-spectrum is shown, but was not used in the analysis. The region of reference (ROR) is shown here as a white dotted line in the bottom row. The contrast maps are obtained from the ORS image and the mean intensity in the ROR, and fitted to the model discussed below. An example of the fit is shown in the right panel. The fit is the red solid line overlapped on to the experimental data (blue squares). Finally, a map of iron concentration in mM is obtained ([Fe]ORS map).

**Figure 2. Validation on a ferritin phantom.** Panel A shows the control image with the nominal iron concentration in mM, per compartment. Panel B shows the ferritin-bound iron map in mM, as obtained with the ORS sequence and the fitting method discussed above. The bright outer rim in the iron map is likely caused by $B_1$ inhomogeneities, since a linear eight-leg birdcage coil with a high filling factor was employed. Panel C shows a comparison between the nominal iron concentration and the fitted one from the method discussed in this work. Blue data with error bars represent the mean and standard deviation of the iron concentration in the ROI drawn in each sample compartment. The red solid line is the identity line and the dashed lines account for the spread in iron loading as reported in literature for horse spleen ferritin from the same producer. Panel D is the Bland-Altman plot of the same data. The black-solid line is the line of equality. The blue line is the bias. The dashed lines enclosing the green area are the limits of agreement. The dotted lines mark the 95% confidence intervals for each estimated statistical quantity.

**Figure 3. Comparison of the quantitative MRI and histological methods to assess tissue iron load on the Alzheimer tissue block:** Top row: MRI $R_2^*$, QSM and ferritin-bound iron mapping. Bottom row: histological staining for myelin, iron (Perl’s and Meguro) and ferritin. Scalebar: 5 mm. The 4th echo of the MGE image is shown for anatomical reference. The pink circle in the MGE image encloses the region of reference (ROR). The panel on the right shows the result of the linear regression analysis between the ROI mean intensity of [Fe]ORS map and the histological staining for iron. The Pearson’s correlation coefficient and p-value are reported on the graph.
**Figure 4.** Comparison of the quantitative MRI and histological methods to assess tissue iron load in the Huntington’s diseases tissue block (labels as above): Scalebar: 5 mm. Abbreviations: IC=internal capsule, PU=putamen, CN=caudate nucleus. The MGE image displays the third echo.

**Figure 5.** Comparison of the quantitative MRI and histological methods to assess tissue iron load on the aceruloplasminemia tissue block (labels as above): Scalebar: 5 mm. Abbreviations: IC=internal capsule, PU=putamen, CN=caudate nucleus, GP=globus pallidus. The MGE image displays the first echo.

**References**

1. Hallgren B, Sourander P. The Effect of Age on the Non-Haemin Iron in the Human Brain. *J Neurochem.* 1958;3(1):41-51. doi:10.1111/j.1471-4159.1958.tb12607.x

2. Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecc L. The role of iron in brain ageing and neurodegenerative disorders. *Lancet Neurol.* 2014;13(10):1045-1060. doi:10.1016/S1474-4422(14)70117-6

3. Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. *Nat Rev Neurosci.* 2004;5(11):863-873. doi:10.1038/nrn1537

4. Li K, Reichmann H. Role of iron in neurodegenerative diseases. *J Neural Transm.* 2016;123(4):389-399. doi:10.1007/s00702-016-1508-7

5. Daugherty AM, Raz N. Appraising the Role of Iron in Brain Aging and Cognition: Promises and Limitations of MRI Methods. *Neuropsychol Rev.* 2015;25(3):272-287. doi:10.1007/s11065-015-9292-y

6. Harman D. Aging: a theory based on free radical and radiation chemistry. *J Gerontol.* 1956;11(3):298-300. doi:10.1093/geronj/11.3.298

7. Ashraf A, Clark M, So PW. The aging of iron man. *Front Aging Neurosci.* 2018;10(MAR):1-23. doi:10.3389/fnagi.2018.00065

8. Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. *Cell.* 2017;171(2):273-285. doi:10.1016/j.cell.2017.09.021
9. Angeli JPF, Shah R, Pratt DA, Conrad M. Ferroptosis Inhibition: Mechanisms and Opportunities. *Trends Pharmacol Sci.* 2017;38(5):489-498. doi:10.1016/j.tips.2017.02.005

10. Ong W, Farooqui AA. Iron, neuroinflammation, and Alzheimer’s disease. 2005;8:183-200.

11. Rivera-Mancía S, Pérez-Neri I, Ríos C, Tristán-López L, Rivera-Espinosa L, Montes S. The transition metals copper and iron in neurodegenerative diseases. *Chem Biol Interact.* 2010;186(2):184-199. doi:10.1016/j.cbi.2010.04.010

12. Rosas HD, Chen YI, Doros G, et al. Alterations in brain transition metals in Huntington disease: An evolving and intricate story. *Arch Neurol.* 2012;69(7):887-893. doi:10.1001/archneurol.2011.2945

13. Miyajima H. Aceruloplasminemia. *Neuropathology.* 2015;35(1):83-90. doi:10.1111/neup.12149

14. Finazzi D, Arosio P. Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. *Arch Toxicol.* 2014;88(10):1787-1802. doi:10.1007/s00204-014-1329-0

15. Arosio P, Elia L, Poli M. Ferritin, cellular iron storage and regulation. *IUBMB Life.* 2017;69(6):414-422. doi:10.1002/iub.1621

16. Quintana C, Gutiérrez L. Could a dysfunction of ferritin be a determinant factor in the aetiology of some neurodegenerative diseases? *Biochim Biophys Acta - Gen Subj.* 2010;1800(8):770-782. doi:10.1016/j.bbagen.2010.04.012

17. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: Birth of a biomarker? *NMR Biomed.* 2004;17(7):433-445. doi:10.1002/nbm.922

18. Makhlouf SA, Parker FT, Berkowitz AE. Magnetic hysteresis anomalies in ferritin. *Phys Rev B.* 1997;55(22):R14717-R14720. doi:10.1103/PhysRevB.55.R14717

19. Schenck JF. Health and Physiological Effects of Human Exposure to Whole-Body Four-Tesla Magnetic Fields during MRI. *Ann N Y Acad Sci.* 1992;649(1 Biological Ef):285-301. doi:10.1111/j.1749-6632.1992.tb49617.x

20. Salgado JC, Olivera-Nappa A, Gerdten ZP, et al. Mathematical modeling of the dynamic storage of iron in ferritin. *BMC Syst Biol.* 2010;4. doi:10.1186/1752-0509-4-147

21. Kakhlon O, Gruenbaum Y, Cabantchik ZL. Repression of ferritin expression increases the labile
iron pool, oxidative stress, and short-term growth of human erythroleukemia cells. *Blood*. 2001;97(9):2863-2871. doi:10.1182/blood.V97.9.2863

22. Ghassaban K, Liu S, Jiang C, Haacke EM. Quantifying iron content in magnetic resonance imaging. *Neuroimage*. 2019;187(October 2017):77-92. doi:10.1016/j.neuroimage.2018.04.047

23. Chavhan GB, Babyn PS, Thomas B, Shroff MM, Haacke EM. Principles, Techniques, and Applications of T2*-based MR Imaging and Its Special Applications. *Radiogr Educ Exhib*. 2009;29(5):1433-1449. doi:10.1148/rg.295095034

24. Brass SD, Chen NK, Mulkern RV, Bakshi R. Magnetic resonance imaging of iron deposition in neurological disorders. *Top Magn Reson Imaging*. 2006;17(1):31-40. doi:10.1097/01.rmr.0000245459.82782.e4

25. Bartzokis G, Sultzer D, Mintz J, et al. In vivo evaluation of brain iron in Alzheimer’s disease and normal subjects using MRI. *Biol Psychiatry*. 1994;35(7):480-487. doi:10.1016/0006-3223(94)90047-7

26. Bartzokis G, Lu PH, Tishler TA, et al. Myelin Breakdown and Iron Changes in Huntington’s Disease: Pathogenesis and Treatment Implications. *Neurochem Res*. 2007;32(10):1655-1664. doi:10.1007/s11064-007-9352-7

27. Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer’s disease detected in vivo with magnetic resonance imaging. *J Alzheimer’s Dis*. 2013;37(1):127-136. doi:10.3233/JAD-130209

28. Langkammer C, Krebs N, Goessler W, et al. Quantitative MR Imaging of Brain Iron: A Postmortem Validation Study. *Radiology*. 2010;257(2):455-462. doi:10.1148/radiol.10100495

29. Haacke EM, Cheng NYC, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. *Magn Reson Imaging*. 2005;23(1):1-25. doi:10.1016/j.mri.2004.10.001

30. Langkammer C, Schweser F, Krebs N, et al. Neurolmage Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. 2012;62:1593-1599. doi:10.1016/j.neuroimage.2012.05.049

31. Eskreis-Winkler S, Zhang Y, Zhang J, et al. The clinical utility of QSM: disease diagnosis, medical management, and surgical planning. *NMR Biomed*. 2017;30(4). doi:10.1002/nbm.3668
Hametner S, Endmayr V, Deistung A, et al. The influence of brain iron and myelin on magnetic susceptibility and effective transverse relaxation - A biochemical and histological validation study. *Neuroimage*. 2018;179(February):117-133. doi:10.1016/j.neuroimage.2018.06.007

Li T-Q, Yao B, van Gelderen P, et al. Characterization of T(2)* heterogeneity in human brain white matter. *Magn Reson Med*. 2009;62(6):1652-1657. doi:10.1002/mrm.22156

Stüber C, Morawski M, Schäfer A, et al. Myelin and iron concentration in the human brain: A quantitative study of MRI contrast. *Neuroimage*. 2014;93:95-106. doi:10.1016/j.neuroimage.2014.02.026

Wharton S, Bowtell R. Fiber orientation-dependent white matter contrast in gradient echo MRI. *Proc Natl Acad Sci U S A*. 2012;109(45):18559-18564. doi:10.1073/pnas.1211075109

Möller HE, Bossoni L, Connor JR, et al. Iron, Myelin, and the Brain: Neuroimaging Meets Neurobiology. *Trends Neurosci*. 42(6):384-401. doi:10.1016/j.tins.2019.03.009

Tanimoto A, Oshio K, Suematsu M, Pouliquen D, Stark DD. Relaxation effects of clustered particles. *J Magn Reson Imaging*. 2001;14(1):72-77. doi:10.1002/jmri.1153

Gossuin Y, Gillis P, Muller RN, Hocq A. Relaxation by clustered ferritin: A model for ferritin-induced relaxation in vivo. *NMR Biomed*. 2007;20(8):749-756. doi:10.1002/nbm.1140

Zurkiya O, Hu X. Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles. *Magn Reson Med*. 2006;56(4):726-732. doi:10.1002/mrm.21024

Delangre S, Vuong QL, Henrard D, Po C, Gallez B, Gossuin Y. Bottom-up study of the MRI positive contrast created by the Off-Resonance Saturation sequence. *J Magn Reson*. 2015;254:98-109. doi:10.1016/j.jmr.2015.02.014

Jian N, Dowle M, Horniblow RD, Tselepis C, Palmer RE. Morphology of the ferritin iron core by aberration corrected scanning transmission electron microscopy. *Nanotechnology*. 2016;27(46):46LT02. doi:10.1088/0957-4484/27/46/46LT02

Li W, Avram A V, Wu B, Xiao X, Liu C. Integrated Laplacian-based phase unwrapping and background phase removal for quantitative susceptibility mapping. 2014;(August 2013):219-227. doi:10.1002/nbm.3056

Li W, Wang N, Yu F, et al. A method for estimating and removing streaking artifacts in
quantitative susceptibility mapping. *Neuroimage*. 2015;108:111-122.
doi:10.1016/j.neuroimage.2014.12.043

44. Zijl P van, Yadav N. Chemical exchange saturation transfer (CEST): what is in a name and what isn’t? *Magn Reson Med*. 2011;65(4):927-948. doi:10.1002/mrm.22761.

45. Vuong QL, Berret JF, Fresnais J, Gossuin Y, Sandre O. A universal scaling law to predict the efficiency of magnetic nanoparticles as MRI T2-contrast agents. *Adv Healthc Mater*. 2012;1(4):502-512. doi:10.1002/adhm.201200078

46. Delangre S, Vuong QL, Po C, Gallez B, Gossuin Y. Improvement of the Off-Resonance Saturation, an MRI sequence for positive contrast with SPM particles: Theoretical and experimental study. *J Magn Reson*. 2016;265:99-107. doi:10.1016/j.jmr.2016.02.002

47. Matt A. Bernstein, Kevin F. King XJZ. *Handbook of MRI Pulse Sequences*.; 2004.
doi:10.4314/bcse.v21i3.21211

48. van Duijn S, Nabuurs RJA, van Duinen SG, Natté R. Comparison of histological techniques to visualize iron in paraffin-embedded brain tissue of patients with Alzheimer’s disease. *J Histochem Cytochem*. 2013;61(11):785-792. doi:10.1369/0022155413501325

49. Bland DGA and JM. Measurement in Medicine : The Analysis of Method Comparison Studies Author (s) : D . G . Altman and J . M . Bland Published by : Blackwell Publishing for the Royal Statistical Society Stable URL : http://www.jstor.org/stable/2987937. 2008;32(3):307-317.

50. Giavarina D. Understanding Bland Altman analysis. *Biochem Medica*. 2015;25(2):141-151.
doi:10.11613/BM.2015.015

51. Bulk M, Abdelmoula WM, Geut H, et al. Quantitative MRI and laser ablation-inductively coupled plasma-mass spectrometry imaging of iron in the frontal cortex of healthy controls and Alzheimer’s disease patients. *Neuroimage*. 2020;215(April):116808.
doi:10.1016/j.neuroimage.2020.116808

52. Damulina A, Pirpamer L, Soellradl M, et al. Cross-sectional and Longitudinal Assessment of Brain Iron Level in Alzheimer Disease Using 3-T MRI. *Radiology*. 2020;(15):192541.
doi:10.1148/radiol.2020192541

53. Bulk M, Kenkhuis B, Van Der Graaf LM, Goeman JJ, Natté R, Van Der Weerd L. Postmortem T2*-Weighted MRI Imaging of Cortical Iron Reflects Severity of Alzheimer’s Disease. *J Alzheimer’s Dis*. 2018;65(4):1125-1137. doi:10.3233/JAD-180317
van Bergen JMG, Li X, Hua J, et al. Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. Sci Rep. 2016;6(March):35514. doi:10.1038/srep35514

van der Weerd L, Lefering A, Webb A, et al. Effects of Alzheimer’s disease and formalin fixation on the different mineralised-iron forms in the human brain. Sci Rep. 2020;10(16440):2020.06.02.129593. doi:10.1101/2020.06.02.129593

Bulk M, van der Weerd L, Breimer W, et al. Quantitative comparison of different iron forms in the temporal cortex of Alzheimer patients and control subjects. Sci Rep. 2018;8(1):6898. doi:10.1038/s41598-018-25021-7

Tao Y, Wang Y, Rogers JT, Wang F. Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: A systematic review and meta-analysis. J Alzheimer’s Dis. 2014;42(2):679-690. doi:10.3233/JAD-140396

House MJ, St. Pierre TG, McLean C. 1.4T study of proton magnetic relaxation rates, iron concentrations, and plaque burden in Alzheimer’s disease and control postmortem brain tissue. Magn Reson Med. 2008;60(1):41-52. doi:10.1002/mrm.21586

Xiaojun Yu, MS Tingting Du, MS Ning Song, PhD Qing He, MS Yong Shen, PhD Hong Jiang, PhD Junxia Xie P. Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease. Neurology. 2013;80(5):492-495. doi:10.1212/01.wnl.0000435455.95141.16

Bartzokis G, Cummings J, Perlman S, Hance DB, Mintz J. Increased basal ganglia iron levels in Huntington disease. Arch Neurol. 1999;56(5):569-574. doi:10.1001/archneur.56.5.569

Dominguez D JF, Ng ACL, Poudel G, et al. Iron accumulation in the basal ganglia in Huntington’s disease: Cross-sectional data from the IMAGE-HD study. J Neurol Neurosurg Psychiatry. 2016;87(5):545-549. doi:10.1136/jnnp-2014-310183

Jurgens CK, Jasinschi R, Ekin A et al. MRI T2 hypointensities in basal ganglia of premanifest Huntington’s disease. Plos Curr Huntingt Dis. 2010;(2:RNN1173).

Jiri M.G. van Bergen, MSc, Jun Hua, PhD, Paul G. Unschuld, MD IAL, Lim, PhD, Craig K. Jones, PhD, Russell L. Margolis, MD, Christopher A. Ross M, PhD, Peter C.M. van Zijl, PhD, and Xu Li P. Quantitative susceptibility mapping suggests altered brain iron in premanifest Huntington’s disease. AJNR Am J Neuroradiol. 2016;5(37):789-796. doi:10.3174/ajnr.A4617 Quantitative

Sánchez-Castañeda C, Squitieri F, Di Paola M, Dayan M, Petrollini M, Sabatini U. The role of
iron in gray matter degeneration in huntington’s disease: A magnetic resonance imaging
study. Hum Brain Mapp. 2015;36(1):50-66. doi:10.1002/hbm.22612

65. Vroegindeweij, Lena H.P., Lucia Bossoni AJWB, Wilson JHP, Bulk M, et al. Quantification of
different iron forms in the aceruloplasminemia brain to explore iron-related
neurodegeneration. medRxiv. 2020. https://doi.org/10.1101/2020.10.15.20206102.

66. Jeong SY, David S. Age-Related Changes in Iron Homeostasis and Cell Death in the Cerebellum
of Ceruloplasmin-Deficient Mice. 2006;26(38):9810-9819. doi:10.1523/JNEUROSCI.2922-06.2006

67. Kaneko K, Hineno A, Yoshida K. Extensive brain pathology in a patient with
aceruloplasminemia with a prolonged duration of illness. Hum Pathol. 2012;43(3):451-456.
doi:10.1016/j.humpath.2011.05.016

68. K. Kaneko, K. Yoshida KA et al. Astrocytic Deformity and Globular Structures Are
Characteristic of the Brains of Patients with Aceruloplasminemia. J Neuropathol Exp Neurol.
2002;61(12):1069-1077.

69. Zhou L, Chen Y, Li Y, et al. Intracranial iron distribution and quantification in
aceruloplasminemia: A case study. Magn Reson Imaging. 2020;70(December 2019):29-35.
doi:10.1016/j.mri.2020.02.016

70. Shang H-F. Desferrioxamine Treatment of Aceruloplasminemia: Long-term Follow-up. Mov
Disord. 2011;26(11):2131-2147. doi:10.1002/mds.23768

71. Brooks RA, Vymazal J, Goldfarb RB, Bulte JWM, Aisen P. Relaxometry and Magnetometry of
Ferritin. Magn Reson Med. 1998;(40):227-235.

72. Brooks RA, Vymazal J, Bulte JW, Baumgarner CD, Tran V. Comparison of T2 relaxation in
blood, brain, and ferritin. J Magn Reson Imaging. 1995;5(4):446-450.
doi:10.1002/jmri.1880050414

73. Bartzokis G, Aravagiri M, Oldendorf WH, Mintz J, Marder SR. Field dependent transverse
relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med.
1993;29(4):459-464. doi:10.1002/mrm.1910290406

74. Smith SA, Bulte JWM, van Zijl PCM. Direct saturation MRI: Theory and application to imaging
brain iron. Magn Reson Med. 2009;62(2):384-393. doi:10.1002/mrm.21980
75. Duyn JH, Schenck J. Contributions to magnetic susceptibility of brain tissue. *NMR Biomed.* 2017;30(4):1-37. doi:10.1002/nbm.3546

76. Kirschvink JL, Kobayashi-Kirschvink a, Woodford BJ. Magnetite biomineralization in the human brain. *Proc Natl Acad Sci U S A.* 1992;89(August):7683-7687. doi:10.1073/pnas.89.16.7683

77. Dedman DJ, Treffry a, Candy JM, et al. Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer’s-disease and chronic renal-dialysis patients. *Biochem J.* 1992;287 (Pt 2):509-514.

78. Lee H, Baek SY, Chun SY, Lee JH, Cho HJ. Specific visualization of neuromelanin-iron complex and ferric iron in the human post-mortem substantia nigra using MR relaxometry at 7T. *Neuroimage.* 2018;172(November 2017):874-885. doi:10.1016/j.neuroimage.2017.11.035
Non-saturated SSFP image → ORS SSFP images → Calculate and inspect Z-spectrum

Choose reference region with no or little [Fe] → X → Calculate contrast (C) maps → Fit contrast data (C vs $\nu_0$)

[Fe]ORS map → ROI analysis
**MRI**

- **MGE**
- **R₂⁺ [ms⁻¹]**
- **QSM [ppm]**
- **[Fe]ORS map [mM]**

**Histology**

- **Myelin**
- **Iron (Perl's)**
- **Ferritin**
- **Iron (Meguro)**

---

![Graph](image)

- **ρ = 0.631**
- **p = 0.0002**
Iron (Meguro) Myelin Iron (Perl's) 
QSM [ppm] MGE $R_2^*$ [ms$^{-1}$] 
MRI 

Histology
Ferritin

MGE

$R_2^*$ [ms$^{-1}$]
QSM [ppm]

[Fe]$_{ORS}$ map [mM]

Histology - mean intensity

[Fe] map - mean intensity

$\rho = 0.622$
$p = 0.0002$